Want to see AU:RHY full AI Analyst Report?

Rhythm Biosciences Ltd. (RHY) Price & Analysis

13 Followers

RHY Stock Chart & Stats

AU$0.09

-AU$0.01(-11.11%)

At close: Jul 27 4:00 PM EDT

AU$0.09

-AU$0.01(-11.11%)

Day’s Range― - ―

52-Week RangeAU$0.06 - AU$0.28

Previous CloseN/A

Volume360.17K

Average Volume (3M)462.98K

Market Cap

AU$28.76M

Enterprise ValueAU$37.54M

Total Cash (Recent Filing)AU$1.73M

Total Debt (Recent Filing)AU$262.44K

Price to Earnings (P/E)―

Beta1.09

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding364,059,840

10 Day Avg. Volume510,821

30 Day Avg. Volume462,976

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)22.03

Price to Sales (P/S)4.56

P/FCF Ratio-4.94

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High Gross Margin & Improving FCFA high gross margin combined with an improving free cash flow trend indicates the business has strong unit economics and a pathway toward cash generation. Over 2-6 months this supports durability: as volumes scale, gross margin can drive incremental profitability and improving FCF reduces reliance on external financing.

Focused Product Pipeline (ColoSTAT)A clear, focused product strategy centered on a blood-based colorectal cancer screening test targets a large, recurring screening market. Structural demand for earlier, easier detection supports long-term commercial potential and strategic partnerships, providing a durable competitive opportunity if clinical and regulatory progress continues.

Relatively Stable Equity RatioA relatively stable equity ratio suggests the company has not excessively diluted shareholders to date and retains a degree of capital structure stability. This can preserve negotiating leverage with investors and creditors, supporting funding options and runway over the medium term despite current losses.

Bears Say

Sharp Revenue DeclineA 42.87% revenue decline signals weak commercial traction or lumpy sales and creates structural headwinds for scaling. Persistent top-line contraction undermines operating leverage, makes investment planning harder, pressures margins, and increases the likelihood of further capital raises to fund commercialization.

Persistent UnprofitabilityNegative net margins and negative EBIT/EBITDA indicate operations are not cash-generative and cost base currently exceeds revenue. Over months this forces reliance on external financing, limits reinvestment in commercialization, and raises dilution risk, constraining sustainable growth and competitive positioning.

Weak Operating Cash Flow And LeverageNegative operating cash flow combined with elevated leverage (debt-to-equity reported at 1.68) heightens financial strain, increases interest and covenant risk, and reduces flexibility to fund trials, commercialization, or partnerships. This structural pressure can force suboptimal financing or cutbacks.

Rhythm Biosciences Ltd. News

Rhythm Biosciences Builds Momentum in ColoSTAT Rollout and Global Partnerships

The latest update is out from Rhythm Biosciences Ltd. ( ($AU:RHY) ). Rhythm Biosciences reported solid progress in...

1d ago

RHY

Rhythm Biosciences Targets GPs With ColoSTAT Campaign After Market Research

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has issued an announcement. Rhythm Biosciences has completed in-field market research with...

29d ago

RHY

Rhythm Biosciences Frames ASX Position While Emphasising Limits of Investor Presentation

The latest update is out from Rhythm Biosciences Ltd. ( ($AU:RHY) ). Rhythm Biosciences has released an investor...

2M ago

RHY

Rhythm Biosciences expands ColoSTAT access program as clinician uptake grows

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has shared an update. Rhythm Biosciences has expanded its ColoSTAT Clinical Access...

2M ago

RHY

Rhythm Biosciences’ ColoSTAT Test Gains Early Clinical Traction in Underserved CRC Patients

An announcement from Rhythm Biosciences Ltd. ( ($AU:RHY) ) is now available. Rhythm Biosciences reported early clinical adoption...

3M ago

RHY

Rhythm Biosciences Schedules Investor Webinar to Update on Cancer Diagnostics Progress

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has shared an announcement. Rhythm Biosciences will host an investor webinar on...

3M ago

RHY

Rhythm Biosciences Cuts Underwritten Options Proceeds After Administrative Error

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has provided an update. Rhythm Biosciences has revised the final proceeds from...

3M ago

RHY

Rhythm Biosciences Seeks ASX Quotation for New Options

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has issued an update. Rhythm Biosciences has applied to the ASX for...

3M ago

RHY

Rhythm Biosciences Issues New Shares and Confirms Regulatory Compliance

An update from Rhythm Biosciences Ltd. ( ($AU:RHY) ) is now available. Rhythm Biosciences has issued 18,834,007 ordinary...

4M ago

RHY

Rhythm Biosciences Seeks ASX Quotation for 18.8 Million New Shares

The latest update is out from Rhythm Biosciences Ltd. ( ($AU:RHY) ). Rhythm Biosciences has applied to the...

4M ago

RHY

RHY FAQ

What was Rhythm Biosciences Ltd.’s price range in the past 12 months?

Rhythm Biosciences Ltd. lowest share price was AU$0.06 and its highest was AU$0.28 in the past 12 months.

What is Rhythm Biosciences Ltd.’s market cap?

Rhythm Biosciences Ltd.’s market cap is AU$28.76M.

When is Rhythm Biosciences Ltd.’s upcoming earnings report date?

Rhythm Biosciences Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 27 days.

How were Rhythm Biosciences Ltd.’s earnings last quarter?

Rhythm Biosciences Ltd. released its earnings results on Feb 18, 2026. The company reported -AU$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.007.

Is Rhythm Biosciences Ltd. overvalued?

According to Wall Street analysts Rhythm Biosciences Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Rhythm Biosciences Ltd. pay dividends?

Rhythm Biosciences Ltd. does not currently pay dividends.

What is Rhythm Biosciences Ltd.’s EPS estimate?

Rhythm Biosciences Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Rhythm Biosciences Ltd. have?

Rhythm Biosciences Ltd. has 364,059,840 shares outstanding.

What happened to Rhythm Biosciences Ltd.’s price movement after its last earnings report?

Rhythm Biosciences Ltd. reported an EPS of -AU$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.381%.

Which hedge fund is a major shareholder of Rhythm Biosciences Ltd.?

Currently, no hedge funds are holding shares in AU:RHY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Rhythm Biosciences Ltd. Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-47.76%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Rhythm Biosciences Ltd.

Rhythm Biosciences Limited functions as a forward-thinking enterprise focused on predictive cancer diagnostics, active across both Australian and global territories. The company's core operations involve the creation, advancement, and market introduction of cutting-edge medical diagnostic technologies. A key innovation is ColoSTAT, their specialized blood test designed for the prompt and reliable identification of colorectal cancer. Established in 2017, the firm's main offices are located in Parkville, Australia.